A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
WiNK is a Phase I/IIa trial to evaluate the safety and efficacy of oNKord® in 33 adults with
acute myeloid leukemia (AML) who are in morphologic complete remission with residual
measurable disease and with no strong indication for hematopoietic stem cell transplantation.